Compare · LONA vs REGN
LONA vs REGN
Side-by-side comparison of LeonaBio Inc. (LONA) and Regeneron Pharmaceuticals Inc. (REGN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. LONA focuses on Biotechnology: Biological Products (No Diagnostic Substances), while REGN focuses on Biotechnology: Pharmaceutical Preparations.
- REGN is the larger of the two at $95.24B, about 3605.8x LONA ($26.4M).
- REGN has been more active in the news (22 items in the past 4 weeks vs 4 for LONA).
- REGN has more recent analyst coverage (25 ratings vs 4 for LONA).
- Company
- LeonaBio Inc.
- Regeneron Pharmaceuticals Inc.
- Price
- -
- -
- Market cap
- $26.4M
- $95.24B
- 1M return
- -
- +12.42%
- 1Y return
- -
- +20.99%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- 1991
- News (4w)
- 4
- 22
- Recent ratings
- 4
- 25
Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults. In addition, the company offers Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer. Further, it offers Inmazeb injection for infection caused by Zaire ebolavirus; and develops product candidates for treating patients with eye, allergic and inflammatory, cancer, cardiovascular and metabolic, pain, infectious, and other diseases. The company has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services. It has collaborations with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.
Latest LONA
- LeonaBio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- LeonaBio Reports Third Quarter 2026 Financial Results and Provides Business Update
- SEC Form SCHEDULE 13G filed by LeonaBio Inc.
- SEC Form SCHEDULE 13G filed by LeonaBio Inc.
- Large owner Portman David J. bought $9,919,161,281 worth of shares (3,149,470 units at $3,149.47) (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13D/A filed by LeonaBio Inc.
- SEC Form 4 filed by LeonaBio Inc.
- LeonaBio Inc. filed SEC Form 8-K: Other Events
- SEC Form 3 filed by new insider Portman David J.
- LeonaBio to Participate in Cantor Global Healthcare Conference 2026
Latest REGN
- SEC Form S-8 filed by Regeneron Pharmaceuticals Inc.
- FDA Approval for LIVSAYIS issued to REGENERON PHARMACEUTICALS
- Regeneron Highlights New Data Across Malignant and Classical Hematology Programs at American Society of Hematology (ASH)
- Livsayis™ (cemdisiran) Approved by the FDA as First and Only siRNA Therapy in Generalized Myasthenia Gravis and Only Treatment with Four-Times-a-Year Subcutaneous Dosing
- Director George L Sing sold $1,917,945 worth of shares (2,000 units at $958.97), decreasing direct ownership by 8% to 23,147 units (SEC Form 4)
- EVP Commercial Marion Mccourt sold $543,504 worth of shares (566 units at $960.25) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 10,305 units (SEC Form 4)
- Co-Chief Scientific Officer Andrew J Murphy exercised 17,000 shares at a strike of $381.92, covered exercise/tax liability with 11,989 shares and sold $4,799,336 worth of shares (5,011 units at $957.76) as part of a pre-agreed trading plan (SEC Form 4)
- Libtayo® (cemiplimab) Approved in the European Union (EU) for Extended Dosing and Faster Infusion Times Across Skin, Lung and Cervical Cancer Indications
- POTS Phase 2 Trial Shows Baloncibart, a First-in-Class NPR1 Blocking Antibody, Reduced Orthostatic Heart Rate and Improved Orthostatic Symptoms
- CIDEB siRNA Normalizes Liver Fat and Improves Liver Injury Markers in MASLD Patients, as Highlighted at AASLD